Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an update.
Shanghai Bio-heart Biological Technology Co., Ltd. has announced a board meeting scheduled for August 26, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology sector. The company focuses on developing biological technologies and solutions, with a market presence in Hong Kong as indicated by its stock listing.
Average Trading Volume: 1,013,046
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.72B
See more insights into 2185 stock on TipRanks’ Stock Analysis page.